Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Jabbour, E., Merchant, A., Wang, T., Vandendries, E., Neuhof, A., Advani, A., Kantarjian, H. NATURE PUBLISHING GROUP. 2019: 149–51

View details for Web of Science ID 000487707800154